News Releases

September 4, 2024

Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

August 14, 2024

Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress

August 13, 2024

Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial

August 8, 2024

Apollomics to Present at the Canaccord Genuity 44th Annual Growth Conference

July 16, 2024

Apollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement

July 3, 2024

Apollomics Announces Updated Strategic Focus and Leadership Team Changes

June 4, 2024

Apollomics Announces Vebreltinib Data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

May 29, 2024

Apollomics Announces Presentation at the 2024 BIO International Convention

May 8, 2024

Apollomics Announces Private Placement Financing and Addition to Board of Directors

April 25, 2024

Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene